Skip to main content
Deciphera
Deciphera
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • DCC-3084
    • DCC-3009
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • DCC-3084
    • DCC-3009
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin

News

News

Archive
August 29, 2018

Deciphera Pharmaceuticals, Inc. to Participate in Citi’s 13th Annual Biotech Conference

Archive
August 7, 2018

Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results

Archive
August 1, 2018

Deciphera Pharmaceuticals, Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference

Archive
June 20, 2018

Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

Archive
June 13, 2018

Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities 2018 Life Sciences Conference

Archive
June 11, 2018

Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock

Archive
June 6, 2018

Deciphera Pharmaceuticals Announces Pricing of Public Offering

Archive
June 4, 2018

Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock

Archive
June 2, 2018

Deciphera Pharmaceuticals Reports Updated Interim Phase 1 Clinical Study Results with DCC-2618 at The 2018 American Society of Clinical Oncology Annual Meeting (ASCO) and Provides Additional Clinical and Regulatory Updates on DCC-2618

Archive
May 29, 2018

Deciphera Pharmaceuticals Appoints Stephen B. Ruddy, Ph.D. as Chief Technical Officer

Pagination

  • First page ‹‹ First
  • Previous page ‹ Prev
  • …
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Current page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • …
  • Next page Next ›
  • Last page Last ››
Displaying 181 - 190 of 265
Deciphera
twitter linkedin
contact us
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • DCC-3084
    • DCC-3009
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Recruiting Privacy Policy
  • Web Accessibility Statement
  • Compliance Hotline

© 2025 Deciphera Pharmaceuticals, LLC. The following are registered trademarks of Deciphera Pharmaceuticals, LLC: QINLOCK, the QINLOCK logo, DECIPHERA, and the Deciphera logo. The following are trademarks of Deciphera Pharmaceuticals, LLC: ROMVIMZA and the ROMVIMZA logo.

Back to top